Last reviewed · How we verify
Atripla
At a glance
| Generic name | Atripla |
|---|---|
| Also known as | EFV/TDF/FTC 600/200/300mg Oral Tablet, tenofovir = Viread®, emtricitabine = Emtriva® (formerly Coviracil), tenofovir + emtricitabine = Truvada®, efavirenz = Sustiva® and Stocrin® |
| Sponsor | Professor Francois Venter |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (PHASE4)
- Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028) (PHASE2)
- Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) (PHASE3)
- REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment (PHASE4)
- Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women (PHASE2)
- Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 (PHASE4)
- Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens
- A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |